Ireland
--:--IST
Latest
PulseAI of Belfast Says FDA Cleared Its Wearable ECG AI Airmid Éireann 1.6 Adds India and China Trials, Swiss Prices Irish Cancer Trial Enrolment at 2.9%, Under Half 6% Target FDA Accelerated Approval for J&J's Head and Neck Cancer Drug Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda ArrayPatch Closes €3.2m Seed for GLP-1 Microneedle Patch PulseAI of Belfast Says FDA Cleared Its Wearable ECG AI Airmid Éireann 1.6 Adds India and China Trials, Swiss Prices Irish Cancer Trial Enrolment at 2.9%, Under Half 6% Target FDA Accelerated Approval for J&J's Head and Neck Cancer Drug Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda ArrayPatch Closes €3.2m Seed for GLP-1 Microneedle Patch
Clinical Trials in China / NCT02954419
Recruiting Observational

IgA Nephropathy Biomarkers Evaluation Study (INTEREST)

NCT02954419 · tracked via the Priya Life Science China tracker
Sponsor
Sun Yat-sen University
Phase
Observational
Started
2016-11
Last updated
2026-04-13

Condition(s) studied

IgA NephropathyGlomerular Diseases

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with relatively normal kidney function (eGFR≥60 ml/min/1.73 m2).

Eligibility

Sex
ALL
Min age
14 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female individuals aged 14 years or older * Patients with biopsy-proven primary IgA nephropathy * A renal biopsy available for reviewing must include 10 or more glomeruli. * The first renal biopsy was performed within 3 years. * eGFR ≥ 60 ml/min/1.73 m2 (MDRD formula); * Individuals or their legal representative who are able to understand and have voluntarily signed the informed consent form (ICF). Exclusion Criteria: * Relatives were diagnosed with biopsy-proven primary IgA nephropathy; * Individuals had secondary IgA nephropathy due to diseases such as diabetes, chronic liver disease and systemic lupus erythematosus.

Primary outcome measure(s)

  • A doubling of serum creatinine level from baseline — 120 months
  • Progression to end stage renal disease (eGFR<15ml/min/1.73 m2, dialysis or transplantation） — 120 months
  • Death — 120 months

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital,Sun Yat-sen University Guangzhou Guangdong Recruiting

More Sun Yat-sen University trials in China

Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. Active, not recruiting
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL Recruiting
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC Starting soon
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Enrolling by invitation
Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma Recruiting

Other trials for the same condition

Atrasentan in Patients With IgA Nephropathy Active, not recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Recruiting
A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants Starting soon
The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA) Recruiting
Nefecon and Ambrisentan in IgA Nephropathy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02954419 on ClinicalTrials.gov ↗ ← All trials in China